Key Points

  • Suboptimal asparaginase exposure leads to an increased risk of relapse in non–high-risk ALL patients.

  • Therapeutic drug monitoring should be used to identify patients with no asparaginase enzyme activity to ensure treatment efficacy.

Abstract

Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal asparaginase exposure among 1401 children aged 1 to 17 years, diagnosed with ALL between July 2008 and February 2016, treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol (including extended asparaginase exposure [1000 IU/m2 intramuscularly weeks 5-33]). Patients were included with delayed entry at their last administered asparaginase treatment, or detection of SI, and followed until relapse, death, secondary malignancy, or end of follow-up (median, 5.71 years; interquartile range, 4.02-7.64). In a multiple Cox model comparing patients with (n = 358) and without (n = 1043) truncated asparaginase treatment due to clinical toxicity, the adjusted relapse-specific hazard ratio (HR; aHR) was 1.33 (95% confidence interval [CI], 0.86-2.06; P = .20). In a substudy including only patients with information on enzyme activity (n = 1115), the 7-year cumulative incidence of relapse for the 301 patients with truncation of asparaginase treatment or SI (157 hypersensitivity, 53 pancreatitis, 14 thrombosis, 31 other, 46 SI) was 11.1% (95% CI, 6.9-15.4) vs 6.7% (95% CI, 4.7-8.6) for the 814 remaining patients. The relapse-specific aHR was 1.69 (95% CI, 1.05-2.74, P=.03). The unadjusted bone marrow relapse-specific HR was 1.83 (95% CI, 1.07-3.14, P=.03) and 1.86 (95% CI, 0.90- 3.87, P=.095) for any central nervous system relapse. These results emphasize the importance of therapeutic drug monitoring and appropriate adjustment of asparaginase therapy when feasible. This trial was registered at www.clinicaltrials.gov as #NCT03987542.

REFERENCES

1.
Jaffe
N
,
Traggis
D
,
Das
L
, et al
.
L-asparaginase in the treatment of neoplastic diseases in children
.
Cancer Res
.
1971
;
31
(
7
):
942
-
949
.
2.
Ertel
IJ
,
Nesbit
ME
,
Hammond
D
,
Weiner
J
,
Sather
H
.
Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group
.
Cancer Res
.
1979
;
39
(
10
):
3893
-
3896
.
3.
Silverman
LB
,
Gelber
RD
,
Dalton
VK
, et al
.
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
.
Blood
.
2001
;
97
(
5
):
1211
-
1218
.
4.
Pession
A
,
Valsecchi
MG
,
Masera
G
, et al
.
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
.
J Clin Oncol
.
2005
;
23
(
28
):
7161
-
7167
.
5.
Amylon
MD
,
Shuster
J
,
Pullen
J
, et al
.
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study
.
Leukemia
.
1999
;
13
(
3
):
335
-
342
.
6.
Pui
CH
,
Yang
JJ
,
Hunger
SP
, et al
.
Childhood acute lymphoblastic leukemia: progress through collaboration
.
J Clin Oncol
.
2015
;
33
(
27
):
2938
-
2948
.
7.
Vrooman
LM
,
Stevenson
KE
,
Supko
JG
, et al
.
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study–Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
.
J Clin Oncol
.
2013
;
31
(
9
):
1202
-
1210
.
8.
Moghrabi
A
,
Levy
DE
,
Asselin
B
, et al
.
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
.
Blood
.
2007
;
109
(
3
):
896
-
904
.
9.
Pui
C-H
,
Liu
Y
,
Relling
MV
.
How to solve the problem of hypersensitivity to asparaginase?
Pediatr Blood Cancer
.
2018
;
65
(
3
):
e26884
.
10.
Albertsen
BK
,
Grell
K
,
Abrahamsson
J
, et al
.
Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study
.
J Clin Oncol
.
2019
;
37
(
19
):
1638
-
1646
.
11.
Lanvers-Kaminsky
C
.
Asparaginase pharmacology: challenges still to be faced
.
Cancer Chemother Pharmacol
.
2017
;
79
(
3
):
439
-
450
.
12.
Schmiegelow
K
,
Attarbaschi
A
,
Barzilai
S
, et al;
Ponte di Legno Toxicity Working Group
.
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus
.
Lancet Oncol
.
2016
;
17
(
6
):
e231
-
e239
.
13.
Toft
N
,
Birgens
H
,
Abrahamsson
J
, et al
.
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol
.
Eur J Haematol
.
2013
;
90
(
5
):
404
-
412
.
14.
Toft
N
,
Birgens
H
,
Abrahamsson
J
, et al
.
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia
.
Leukemia
.
2018
;
32
(
3
):
606
-
615
.
15.
Frandsen
TL
,
Heyman
M
,
Abrahamsson
J
, et al
.
Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial
.
Eur J Cancer
.
2014
;
50
(
2
):
251
-
259
.
16.
Tram Henriksen
L
,
Gottschalk Højfeldt
S
,
Schmiegelow
K
, et al;
Nordic Society of Pediatric Hematology and Oncology, NOPHO Group
.
Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation
.
Pediatr Blood Cancer
.
2017
;
64
(
12
):
e26686
-
e26688
.
17.
Lanvers
C
,
Vieira Pinheiro
JP
,
Hempel
G
,
Wuerthwein
G
,
Boos
J
.
Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum
.
Anal Biochem
.
2002
;
309
(
1
):
117
-
126
.
18.
Müller
HJ
,
Löning
L
,
Horn
A
, et al
.
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols
.
Br J Haematol
.
2000
;
110
(
2
):
379
-
384
.
19.
Tong
WH
,
Pieters
R
,
Kaspers
GJL
, et al
.
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia
.
Blood
.
2014
;
123
(
13
):
2026
-
2033
.
20.
Ahlke
E
,
Nowak-Göttl
U
,
Schulze-Westhoff
P
, et al
.
Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia
.
Br J Haematol
.
1997
;
96
(
4
):
675
-
681
.
21.
Rizzari
C
,
Citterio
M
,
Zucchetti
M
, et al
.
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia
.
Haematologica
.
2006
;
91
(
1
):
24
-
31
.
22.
Panosyan
EH
,
Seibel
NL
,
Martin-Aragon
S
, et al;
Children’s Cancer Group Study CCG-1961
.
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961
.
J Pediatr Hematol Oncol
.
2004
;
26
(
4
):
217
-
226
.
23.
Gupta
S
,
Wang
C
,
Raetz
EA
, et al
.
Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group (COG)
.
J Clin Oncol
.
2020
;
38
(
17
):
1897
-
1905
.
24.
Avramis
VI
,
Sencer
S
,
Periclou
AP
, et al
.
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study
.
Blood
.
2002
;
99
(
6
):
1986
-
1994
.
25.
Möricke
A
,
Zimmermann
M
,
Reiter
A
, et al
.
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000
.
Leukemia
.
2010
;
24
(
2
):
265
-
284
.
26.
Rizzari
C
,
Valsecchi
MG
,
Aricò
M
, et al;
Associazione Italiano Ematologia Oncologia Pediatrica
.
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study–a report from the Associazione Italiana Ematologia Oncologia Pediatrica
.
J Clin Oncol
.
2001
;
19
(
5
):
1297
-
1303
.
27.
Wolthers
BO
,
Frandsen
TL
,
Abrahamsson
J
, et al
.
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol
.
Leukemia
.
2017
;
31
(
2
):
325
-
332
.
28.
Wolthers
BO
,
Frandsen
TL
,
Baruchel
A
, et al;
Ponte di Legno Toxicity Working Group
.
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study
.
Lancet Oncol
.
2017
;
18
(
9
):
1238
-
1248
.
You do not currently have access to this content.

Sign in via your Institution

Sign In